Genscript BiotechGNNSF 66 Days Payable is 38.80 as of Dec. 2025, which is 19% below its 10-year median of 48.03. GuruFocus rates GNNSF with a GF Score™ of 66/100 and a GF Value™ of $2.48 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 702 Biotechnology companies, Genscript Biotech ranks worse than 77.21% on this metric.
The historical rank and industry rank for Genscript Biotech's Days Payable or its related term are showing as below:
GNNSF'
s Days Payable Range Over the Past 10 Years
Min: 29.91 Med: 48.03 Max: 60.16
Current: 35.41
During the past 12 years, Genscript Biotech's highest Days Payable was 60.16. The lowest was 29.91. And the median was 48.03.
GNNSF's Days Payable is ranked worse than 77.21% of 702
companies
in the Biotechnology industry
Industry Median: 113.56
vs GNNSF: 35.41
Genscript Biotech's Days Payable
declined
from Dec. 2024 (47.60) to Dec. 2025 (38.80).
It may suggest that Genscript Biotechaccelerated paying its suppliers.
Genscript Biotech Days Payable Related Terms
Genscript Biotech Days Payable Historical Data
* Premium members only.
The historical data trend for Genscript Biotech's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GNNSF vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Genscript Biotech's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genscript Biotech Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genscript Biotech's Days Payable distribution charts can be found below:
* The bar in red indicates where Genscript Biotech's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Genscript Biotech's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genscript Biotech (GNNSF) has a Days Payable of 38.80 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Genscript Biotech and its competitors. This is 19% below median its historical median of 48.03. Over the past decade, Genscript Biotech's Days Payable has ranged from 29.91 to 60.16. According to the industry distribution chart, Genscript Biotech ranks #542 out of 702 companies in the Biotechnology industry, placing it in the top 77.2%.
Is Genscript Biotech's Days Payable too high?
Genscript Biotech's current Days Payable of 38.80 is 19% below median its 10-year median of 48.03. Over the past 10 years, this metric has ranged from a low of 29.91 to a high of 60.16. The Biotechnology industry median Days Payable is 113.56. Genscript Biotech's value of 38.80 is 65.8% below this industry median. Based on the distribution chart, Genscript Biotech ranks #542 out of 702 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Genscript Biotech has a GF Score™ of 66/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genscript Biotech's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genscript Biotech ranks #542 out of 702 companies for Days Payable. This places Genscript Biotech in the lower half of its industry. The industry median Days Payable is 113.56. Genscript Biotech's value of 38.80 is 65.8% below this benchmark. Historically, Genscript Biotech's own Days Payable has ranged from 29.91 to 60.16 over the past decade. While the company's 10-year median is 48.03 vs. the industry median of 113.56, Genscript Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genscript Biotech's current Days Payable of 38.80 is 65.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Genscript Biotech and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genscript Biotech's current Days Payable is 38.80, which is 19% below median its own 10-year median of 48.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genscript Biotech stock overvalued right now?
Based on GuruFocus' analysis, Genscript Biotech (GNNSF) is currently considered Significantly Undervalued. The stock's GF Value™ is $2.48, compared to a current price of $1.60 — trading 35.5% below its estimated fair value. The current Days Payable is 38.80, which is 19% below median its 10-year median of 48.03 and 65.8% below the Biotechnology industry median of 113.56. Genscript Biotech's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Genscript Biotech (GNNSF), the current Days Payable is 38.80 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genscript Biotech (GNNSF) Overvalued in 2026?
Based on GuruFocus' analysis, Genscript Biotech stock appears to be undervalued.
The current stock price of $1.60 is trading 35.5% below its estimated GF Value™ of $2.48.
GuruFocus considers Genscript Biotech to be Significantly Undervalued.
Key valuation signals for GNNSF:
Days Payable: 38.80 (19% below median its 10-year median of 48.03)
GF Value™: $2.48 vs. price of $1.60 (35.5% below fair value)
Industry Position: 65.8% below the Biotechnology median (#542 of 702)
No single metric tells the full story. See the GNNSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GenScript Biotech Corp is an investment holding company engaged in the manufacture and sale of life science research products and services, including life science services and products, biologics development services, and industrial synthetic biology products. Its segments include life science services and products, which generate maximum revenue and provide research services and products; biologics development services, which support the development of therapeutic antibodies and CGT products; industrial synthetic biology, which provides enzyme development and production using engineered microbial strains; and the operation unit, which provides shared services. It operates in Mainland China, which generates maximum revenue, U.S., Europe, and the Asia Pacific excluding Mainland China.
66GF Score
Get the complete analysis for GNNSF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GNNSF has been successfully added to your 
